OSE Immunotherapeutics SA (EPA:OSE)
France
· Delayed Price · Currency is EUR 4.250
+0.592 (16.18%)
Apr 28, 2026, 5:35 PM CET
OSE Immunotherapeutics Employees
OSE Immunotherapeutics had 64 employees as of December 31, 2024. The number of employees increased by 9 or 16.36% compared to the previous year.
Employees
64
Change (1Y)
9
Growth (1Y)
16.36%
Revenue / Employee
€27,844
Profits / Employee
€508,109
Market Cap
95.29M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Valerio Therapeutics Société anonyme | 25 |
| Fermentalg | 63 |
| Adocia | 77 |
| THX Pharma Société Anonyme | 10 |
| MaaT Pharma | 65 |
| Innate Pharma | 174 |
| ABIONYX Pharma | 51 |
| Nicox | 5 |
OSE Immunotherapeutics News
- 1 day ago - OSE Immunotherapeutics Welcomes FDA Orphan Drug Designation Granted to Pegrizeprument (VEL-101) for Prevention of Organ Rejection in Heart Transplant Patients - GlobeNewsWire
- 5 days ago - OSE Immunotherapeutics Announces Presentation of TEDOVA Phase 2 Topline Results of Tedopi® in Ovarian Cancer at the ASCO 2026 Meeting - GlobeNewsWire
- 13 days ago - OSE Immunotherapeutics to Present a Novel, First-in-Class, FPR2 Agonist Monoclonal Antibody in the Resolution of Chronic Inflammation at the AAI 2026 Meeting - GlobeNewsWire
- 14 days ago - OSE Immunotherapeutics Evolves its Leadership Team - GlobeNewsWire
- 5 weeks ago - OSE Immunotherapeutics to Present at Upcoming Investor Conferences - GlobeNewsWire
- 6 weeks ago - OSE Immunotherapeutics Announces its 2026 Financial Calendar - GlobeNewsWire
- 7 weeks ago - OSE Immunotherapeutics Confirms Marc Le Bozec As CEO To Drive Next Phase Of Growth - Nasdaq
- 2 months ago - OSE Immunotherapeutics Accelerates Strategic Refocusing to Advance Late Stage Value Drivers Lusvertikimab and Tedopi® - GlobeNewsWire